Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas Therapeutics’ nomination committee for the AGM 2021

Interim Report Q3, 2020

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas closes acquisition of a controlling interest in Genkyotex SA

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

The 200[th] patient’s last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

Number of shares and votes in Calliditas Therapeutics

First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon

Calliditas appoints Group General Counsel

Interim Report Q2, 2020

Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report

Number of shares and votes in Calliditas Therapeutics

Calliditas reorganizes its management team

Exercise of over-allotment option and end of the stabilization period

Number of shares and votes in Calliditas Therapeutics

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market

CEO Renée Aguiar-Lucander exercises warrants and invests SEK 15.7m (appr. USD 1.7m) in Calliditas

Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics’ ADSs traded on The Nasdaq Global Select Market

Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States

Calliditas Therapeutics launches US IPO roadshow and targets a capital raise of MUSD 75

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas publicly files registration statement with SEC for a proposed initial public offering in the United States

Interim Report Q1, 2020

Calliditas Therapeutics’ 2019 Annual Report published

Calliditas provides a corporate business update in the context of the Covid-19 pandemic

Calliditas appoints new Chief Medical Officer

Calliditas strengthens its US Commercial Organization

Calliditas moves its Annual General Meeting 2020 to June 25

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Year-End Report 2019

Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ)

Positive opinion received from EMA Paediatric Committee on the Paediatric Investigation Plan for Nefecon for the treatment of IgAN

Calliditas submits draft registration statement for the listing of ADSs in the U.S.